Table 6

Schedule B investigator-identified and sponsor-assessed DLTs

Patient’s starting dose cohortDose when DLT occurredAE recorded as DLTWas the AE serious?SeverityRelationship to MRZ/DexAction taken with MRZ /DexOutcome
RP2D 0.5 mg/m2 0.5 mg/m2 Nausea Yes Grade 3 MRZ probable/Dex not related None Resolved 
RP2D 0.5 mg/m2 0.5 mg/m2 Confusional state Yes Grade 4 MRZ probable/Dex not related MRZ discontinued Resolved 
0.6 mg/m2 0.4 mg/m2 Gait disturbance No Grade 2 MRZ probable/Dex not related MRZ dose reduced, dose delayed Resolved 
0.6 mg/m2 0.6 mg/m2 Paranoia No Grade 2 MRZ possible/Dex not related MRZ discontinued Resolved 
Patient’s starting dose cohortDose when DLT occurredAE recorded as DLTWas the AE serious?SeverityRelationship to MRZ/DexAction taken with MRZ /DexOutcome
RP2D 0.5 mg/m2 0.5 mg/m2 Nausea Yes Grade 3 MRZ probable/Dex not related None Resolved 
RP2D 0.5 mg/m2 0.5 mg/m2 Confusional state Yes Grade 4 MRZ probable/Dex not related MRZ discontinued Resolved 
0.6 mg/m2 0.4 mg/m2 Gait disturbance No Grade 2 MRZ probable/Dex not related MRZ dose reduced, dose delayed Resolved 
0.6 mg/m2 0.6 mg/m2 Paranoia No Grade 2 MRZ possible/Dex not related MRZ discontinued Resolved 

or Create an Account

Close Modal
Close Modal